Literature DB >> 27891576

Changes in Drug Use and Polypharmacy After the Age of 90: A Longitudinal Study of the Danish 1905 Cohort.

Jonas W Wastesson1, Anna Oksuzyan2, Jacob von Bornemann Hjelmborg3, Kaare Christensen1,3,4,5.   

Abstract

OBJECTIVES: To determine the longitudinal development of drug use in very old adults.
DESIGN: Longitudinal cohort study with waves in 1998, 2000, 2002, and 2005.
SETTING: Nationwide study in Denmark. PARTICIPANTS: All living Danes born in 1905 were approached in 1998; 2,262 responded at baseline. MEASUREMENTS: Self-reported use of regularly taken drugs. Mean and median number of drugs and growth curve models were used to identify the change in number of drugs as the cohort aged from 92 to 100.
RESULTS: The within-person use of drugs increased with age for women (0.19 per year; 95% confidence interval (CI) = 0.15-0.24) and men (0.15 per year; 95% CI = 0.06-0.24). Persons leaving the study prematurely had higher baseline values and a steeper increase in their annual use of drugs. The population-level mean number of drugs increased from baseline (3.6 drugs) to the first follow-up (4.1 drugs) but thereafter remained stable at approximately 4 drugs. Women used more drugs than men at all waves.
CONCLUSION: In this first longitudinal study of drug use in nonagenarians, individuals used an increasing number of drugs as they aged. This increase is difficult to detect in cross-sectional analyses of the population-level mean. More efforts to understand what is reasonable prescribing at these older ages are needed.
© 2016, Copyright the Authors Journal compilation © 2016, The American Geriatrics Society.

Entities:  

Keywords:  aged; drug use; longitudinal; nonagenarians; polypharmacy

Mesh:

Year:  2016        PMID: 27891576      PMCID: PMC5258828          DOI: 10.1111/jgs.14416

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   5.562


  26 in total

1.  Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes.

Authors:  Danijela Gnjidic; Sarah N Hilmer; Fiona M Blyth; Vasi Naganathan; Louise Waite; Markus J Seibel; Andrew J McLachlan; Robert G Cumming; David J Handelsman; David G Le Couteur
Journal:  J Clin Epidemiol       Date:  2012-06-27       Impact factor: 6.437

2.  Completeness and accuracy of interview data from proxy respondents: demographic, medical, and life-style factors.

Authors:  L M Nelson; W T Longstreth; T D Koepsell; H Checkoway; G van Belle
Journal:  Epidemiology       Date:  1994-03       Impact factor: 4.822

Review 3.  Optimising drug treatment for elderly people: the prescribing cascade.

Authors:  P A Rochon; J H Gurwitz
Journal:  BMJ       Date:  1997-10-25

4.  Drug utilization and polypharmacy in an Italian elderly population: the EPIFARM-elderly project.

Authors:  Alessandro Nobili; Carlotta Franchi; Luca Pasina; Mauro Tettamanti; Marta Baviera; Lara Monesi; Carla Roncaglioni; Emma Riva; Ugo Lucca; Angela Bortolotti; Ida Fortino; Luca Merlino
Journal:  Pharmacoepidemiol Drug Saf       Date:  2011-01-24       Impact factor: 2.890

5.  The development of polypharmacy. A longitudinal study.

Authors:  L Veehof; R Stewart; F Haaijer-Ruskamp; B M Jong
Journal:  Fam Pract       Date:  2000-06       Impact factor: 2.267

6.  Increasing use of medicines in elderly persons: a five-year follow-up of the Kuopio 75+Study.

Authors:  Johanna Jyrkkä; Leena Vartiainen; Sirpa Hartikainen; Raimo Sulkava; Hannes Enlund
Journal:  Eur J Clin Pharmacol       Date:  2006-01-12       Impact factor: 2.953

7.  The male-female health-survival paradox: a survey and register study of the impact of sex-specific selection and information bias.

Authors:  Anna Oksuzyan; Inge Petersen; Henrik Stovring; Paul Bingley; James W Vaupel; Kaare Christensen
Journal:  Ann Epidemiol       Date:  2009-05-19       Impact factor: 3.797

8.  A longitudinal evaluation of drug use in an ambulatory elderly population.

Authors:  R B Stewart; M T Moore; F E May; R G Marks; W E Hale
Journal:  J Clin Epidemiol       Date:  1991       Impact factor: 6.437

9.  The enduring effect of education-socioeconomic differences in disability trajectories from age 85 years in the Newcastle 85+ Study.

Authors:  Andrew Kingston; Karen Davies; Joanna Collerton; Louise Robinson; Rachel Duncan; Thomas B L Kirkwood; Carol Jagger
Journal:  Arch Gerontol Geriatr       Date:  2015-02-25       Impact factor: 3.250

10.  Remaining Life Expectancy With and Without Polypharmacy: A Register-Based Study of Swedes Aged 65 Years and Older.

Authors:  Jonas W Wastesson; Vladimir Canudas-Romo; Rune Lindahl-Jacobsen; Kristina Johnell
Journal:  J Am Med Dir Assoc       Date:  2015-09-02       Impact factor: 4.669

View more
  5 in total

Review 1.  The patterns and implications of potentially suboptimal medicine regimens among older adults: a narrative review.

Authors:  Georgie B Lee; Christopher Etherton-Beer; Sarah M Hosking; Julie A Pasco; Amy T Page
Journal:  Ther Adv Drug Saf       Date:  2022-07-04

2.  GP-delivered medication review of polypharmacy, deprescribing, and patient priorities in older people with multimorbidity in Irish primary care (SPPiRE Study): A cluster randomised controlled trial.

Authors:  Caroline McCarthy; Barbara Clyne; Fiona Boland; Frank Moriarty; Michelle Flood; Emma Wallace; Susan M Smith
Journal:  PLoS Med       Date:  2022-01-05       Impact factor: 11.069

3.  Polypharmacy occurrence and the related risk of premature death among older adults in Denmark: A nationwide register-based cohort study.

Authors:  Anna Vera Jørring Pallesen; Maria Kristiansen; Rudi G J Westendorp; Laust Hvas Mortensen
Journal:  PLoS One       Date:  2022-02-23       Impact factor: 3.240

4.  Is polypharmacy associated with mortality in the very old: Findings from the Newcastle 85+ Study.

Authors:  Laurie E Davies; Andrew Kingston; Adam Todd; Barbara Hanratty
Journal:  Br J Clin Pharmacol       Date:  2022-01-27       Impact factor: 3.716

5.  The epidemiology of polypharmacy in older adults: register-based prospective cohort study.

Authors:  Lucas Morin; Kristina Johnell; Marie-Laure Laroche; Johan Fastbom; Jonas W Wastesson
Journal:  Clin Epidemiol       Date:  2018-03-12       Impact factor: 4.790

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.